natgillin/translations-raw huggingface dataset:
The active substance in Mylotarg, gemtuzumab ozogamicin, consists of two parts: a cytotoxic (cellkilling) substance and a monoclonal antibody (a type of protein). 
Učinkovina v zdravilu Mylotarg, gemtuzumab ozogamicin, je sestavljena iz dveh delov: citotoksične (ki uničuje celice) snovi in monoklonskega protitelesa (vrsta beljakovine).
Mylotarg contains the active substance gemtuzumab ozogamicin. 
Mylotarg vsebuje učinkovino gemtuzumab ozogamicin.
Mylotarg, given in combination with daunorubicin and cytarabine, has been shown to prolong the time patients lived before the cancer came back by up to 8 months. 
Izkazalo se je, da zdravilo Mylotarg v kombinaciji z daunorubicinom in citarabinom podaljša čas, ki ga bolniki preživijo pred ponovitvijo raka, za do osem mesecev.
How is Mylotarg used? 
Kako se zdravilo Mylotarg uporablja?
How does Mylotarg work? 
Kako zdravilo Mylotarg deluje?
Mylotarg can only be obtained with a prescription. 
Predpisovanje in izdaja zdravila Mylotarg je le na recept.
Cardboard box containing either 1 or 6 bottles. 
Kartonska škatla vsebuje 1 ali 6 steklenic.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/ . 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/.
Do not store above 25 °C. 
Ne shranjujte pri temperaturi nad 25°C.
For the full list of excipients, see section 6.1. 
Za celoten seznam pomožnih, snovi glejte poglavje 6.1.
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE 
BESEDILO “SAMO ZA ŽIVALI” IN POGOJI IN OMEJITVE GLEDE OSKRBE IN UPORABE, ČE JE SMISELNO
Clear, colourless liquid. 
Bistra, brezbarvna tekočina.
If these symptoms occur, remove the individual from the source of exposure and seek medical attention. 
Če se pojavijo ti simptomi, je treba osebo odstraniti od vira izpostavljenosti in poiskati zdravniško pomoč.
Do not use this veterinary medicinal product after the expiry date which is stated on the label. 
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na nalepki.
Pharmacotherapeutic group: inhalation anaesthetic, ATCvet code: QN 01AB08 
FARMAKOLOŠKE LASTNOSTI Farmakoterapevtska skupina: Inhalacijski anestetik, oznaka ATCvet: QN 01AB08.
Sevohale contains no stabiliser and does not affect the calibration or operation of these vaporisers in any way. 
Sevohale ne vsebuje nobenega stabilizatorja in nikakor ne vpliva na kalibracijo ali delovanje teh hlapilnikov.
250 ml Type III amber glass bottle with a yellow collar on the neck, sealed with a poly-seal cap, and secured with PET film. 
250-ml Type III rjava steklenica z rumeno ovratnico na vratu, zaprta s poli-tesnilno zaporko in zavarovana s PET folijo.
In the dog, sevoflurane may increase intracranial pressure at concentrations of 2.0 MAC and above under normal partial pressures of carbon dioxide (normocapnia), but intracranial pressure has been shown to remain within normal range at sevoflurane concentrations of up to 1.5 MAC if hypocapnia is induced by hyperventilation. 
Sevofluran lahko zviša intrakranialni tlak pri koncentracijah 2,0 MAC in več, pri normalnih parcialnih tlakih ogljikovega dioksida (normokapnija), vendar se je pokazalo, da intrakranialni tlak ostane v normalnih mejah pri koncentracijah sevoflurana do 1,5 MAC, če se hipokapnija inducira s hiperventilacijo.
D OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 
D. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
Limited clinical experience in administering sevoflurane to animals with renal, hepatic and cardiovascular insufficiency suggests that sevoflurane may be safely used in these conditions. 
Omejene klinične izkušnje z uporabo sevoflurana pri živalih z ledvično, jetrno in kardiovaskularno insuficienco kažejo, da lahko sevofluran pri teh boleznih varno uporabljamo.
In dogs exposed to 4% sevoflurane for 3 hours, mean peak maximum serum fluoride concentrations of 20.0 ± 4.8 µmol/l have been observed after 3 hours of anaesthesia. 
Pri psih, izpostavljenih 4-odstotnemu sevofluranu 3 ure dolgo, so opazovali srednji vrh najvišjih serumskih koncentracij fluorida 20,0 ± 4,8 μmol/l po 3 urah anestezije.
Date of first authorisation: 21/06/2016 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 21/06/2016.
100% v/v sevoflurane 
100 % v/v sevofluran
In case of accidental contact with the skin, wash the affected area with abundant water. 
V primeru nehotenega stika s kožo sperite prizadeti predel z obilico vode.
QUALITATIVE AND QUANTITATIVE COMPOSITION 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Zdravilna učinkovina:
Sevohale should be administered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled. 
Sevohale je treba dajati s hlapilnikom, ki je posebej kalibriran za uporabo s sevofluranom, tako da je možno koncentracijo v vdihanem zraku natančno kontrolirati.
Sevohale overdose may result in profound respiratory depression. 
Preveliko odmerjanje Sevohalea lahko povzroči globoko depresijo dihanja.
In dogs, concentrations of sevoflurane below 2.0 MAC result in a small net increase in total liver blood flow. 
Pri psih koncentracije sevoflurana pod 2,0 MAC povzročijo majhno neto zvečanje celotnega pretoka krvi skozi jetra.
4.4 Special warnings for each target species 
4.4 Posebna opozorila za vsako ciljno živalsko vrsto Ni posebnih opozoril.
Sevoflurane 100% v/v 
Sevofluran 100 % v/v.
In order to minimise this reaction in rebreathing anaesthetic circuits, Sevohale should not be passed through soda lime or barium hydroxide that has been allowed to dry out. 
Da to reakcijo v anestezijskih sistemih za povratno dihanje kar najbolj zmanjšamo, sevoflurana ne smemo speljati skozi zmes kalcijevega hidroksida z natrijevim ali kalijevim hidroksidom ali skozi barijev hidroksid, ki smo ga pustili, da se je posušil.
Bottle label 
Kartonska škatla
EU/2/16/196/001-002 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/16/196/001-002
• Care should be taken when dispensing Sevohale, with immediate removal of any spillage. 
• Pri pripravi Sevohalea moramo biti previdni, morebitno razlito zdravilo je treba nemudoma odstraniti.
Limited data are available on the effects of the highly potent alpha-2agonists (medetomidine, romifidine and dexmedetomidine) as premedication. 
O učinkih zelo močnih alfa-2-agonistov (medetomidina, romifidina in deksmedetomidina) kot sredstvih za premedikacijo so na voljo omejeni podatki.
Alpha-2-agonists cause bradycardia which may occur when they are used with sevoflurane. 
Alfa-2agonisti povzročajo bradikardijo, kadar se uporabljajo s sevofluranom.
Anaesthetic regimens that include opioid, alpha-2-agonist, benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations. 
Anestetične sheme, ki vključujejo premedikacijo z opioidi, alfa-2-agonisti, benzodiazepini ali fenotiazini, dopuščajo uporabo nižjih vzdrževalnih koncentracij sevoflurana.
For induction and maintenance of anaesthesia. 
Za uvod v anestezijo in vzdrževanje anestezije.
Dose-dependent respiratory depression is commonly observed while using sevoflurane, therefore respiration should be closely monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted accordingly. 
Od odmerka odvisna depresija dihanja se pogosto opazi pri uporabi sevofluranazato je treba med sevofluransko anestezijo dihanje skrbno spremljati in ustrezno prilagajati koncentracijo sevoflurana v vdihanem zraku.
Sevoflurane produces only modest increases in cerebral blood flow and metabolic rate, and has little or no ability to potentiate seizures. 
Pre psih sevofluran povzroča le zmerno zvišanje možganskega krvnega pretoka in hitrosti presnove in le malo ali sploh ne krepi napade krčev.
To be supplied only on veterinary prescription. 
Samo za živali, na veterinarski recept
Surgical levels of anaesthesia in the healthy dog may be maintained with inhaled concentrations of 3.3 to 3.6% in the presence of premedication. 
Kirurške ravni anestezije pri zdravih psih lahko vzdržujemo z inhaliranimi koncentracijami 3,3 do 3,6 % ob premedikaciji.
Sevohale 100% v/v Inhalation vapour, liquid for dogs and cats. 
Sevohale 100 % v/v para za inhaliranje, tekočina za pse in mačke.
Paddling, retching, salivation, cyanosis, premature ventricular contractions and excessive cardiopulmonary depression have been reported very rarely based on post-authorisation spontaneous reporting experience. 
Veslanje s tacami, vzdigovanje, slinjenje, cianoza, prezgodnji prekatni utripi in čezmerna kardiopulmonalna depresija so zelo redki neželeni učinki o katerih so poročali po pridobitvi dovoljenja za promet z zdravilom.
Sevoflurane may be used for maintenance anaesthesia following mask induction with sevoflurane or following induction with injectable agents. 
Sevofluran lahko uporabljamo za vzdrževalno anestezijo po uvedbi z masko in sevofluranom ali po uvedbi s sredstvi za injiciranje.
In dogs the concurrent administration of thiopental, however, may slightly increase sensitivity to adrenaline induced cardiac arrhythmias. 
Vendar lahko sočasna uporaba tiopentala pri psih rahlo zveča občutljivost za srčne aritmije, inducirane z adrenalinom.
The use of injectable induction agents without premedication has little effect on the concentrations of sevoflurane required for maintenance. 
Uporaba sredstev za uvod v anestezijo, ki se injicirajo, brez premedikacije le malo vpliva na koncentracije sevoflurana, ki so potrebne za vzdrževanje.
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
B. POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE OSKRBE ALI UPORABE
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION 
ODMEREK ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) NAČIN UPORABE IN ZDRAVILA
A minimal amount of sevoflurane is required to be dissolved in the blood before the alveolar partial pressure is in equilibrium with the arterial partial pressure because of the low solubility of sevoflurane in blood (blood/gas partition coefficient at 30 °C is 0.63 to 0.69). 
Zaradi majhne topnosti sevoflurana v krvi (porazdelitveni koeficient med krvjo in plinom pri 30 °C je 0,63 do 0,69) se mora v krvi raztopiti minimalna količina sevoflurana, preden se alveolarni parcialni tlak uravnovesi z arterijskim parcialnim tlakom.
The concentration of sevoflurane necessary to maintain anaesthesia is much less than that required for induction. 
Koncentracija sevoflurana, potrebna za vzdrževanje anestezije, je mnogo manjša od tiste, ki je potrebna za uvod v anestezijo.
Sevoflurane has a variable effect on heart rate, which tends to increase from baseline at low MAC and fall back with increasing MAC. Sevoflurane causes systemic vasodilation and produces dose dependent decreases in mean arterial pressure, total peripheral resistance, cardiac output and possibly the strength of myocardial contraction and speed of myocardial relaxation. 
Sevofluran povzroča sistemsko vazodilatacijo in od odmerka odvisno zmanjšanje srednjega arterijskega tlaka, celotnega perifernega upora, minutnega volumna srca, lahko pa tudi jakosti kontrakcij srčne mišice in hitrosti relaksacije srčne mišice.
• Use a cuffed endotracheal tube when possible for the administration of Sevohale during maintenance anaesthesia. 
• Kadar je možno, uporabljajte za dajanje Sevohalea med vzdrževalno anestezijo endotrahealni tubus z mešičkom.
PACKAGE LEAFLET: Sevohale Inhalation vapour, liquid for dogs and cats, 100% v/v sevoflurane 
NAVODILO ZA UPORABO Sevohale Para za inhaliranje, tekočina za pse in mačke, 100 % v/v sevofluran.
Sevoflurane administration adversely affects the autoregulation of renal blood flow in dogs and cats. 
Uporaba Sevoflurana neugodno vpliva na avtoregulacijo pretoka krvi skozi ledvice pri psih.
which are typically 1.3 to 1.5 times the MAC value. 
Mnogokratniki MAC se uporabljajo kot smernica za kirurške ravni anestezije, ki so tipično 1,3 do 1,5-kratnik vrednosti MAC.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. 
Varnost zdravila v obdobju brejosti in laktacije ni bila ugotovljena..
However, there is limited clinical experience of the use of sevoflurane, after propofol induction, in bitches and queens undergoing caesarean section, without any ill effects being detected in either the bitch or queen, or the puppies or kittens. 
Vendar so z uporabo sevoflurana po uvodu v anestezijo s propofolom pri psicah in mačkah po carskem rezu na voljo omejene klinične izkušnje, pri tem niso odkrili nikakršnih škodljivih učinkov niti pri psici in mački niti pri kužkih ali mačjih mladičih.
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC ODGOVOREN ZA SPROSTITEV SERIJE
Inhalation vapour, liquid. 
Para za inhaliranje, tekočina.
During maintenance of anaesthesia, increasing the concentration of sevoflurane produces a dose dependent decrease in blood pressure. 
Med vzdrževanjem anestezije povzroči zviševanje koncentracije sevoflurana od odmerka odvisno znižanje krvnega tlaka.
In the absence of premedication, inhaled concentrations of sevoflurane in the range of 3.7 to 3.8% will provide surgical levels of anaesthesia in the healthy dog. 
Če premedikacije ni, bodo inhalirane koncentracije sevoflurana v mejah 3,7 do 3,8 % pri zdravem psu povzročile kirurške ravni anestezije.
For operator warnings - read the package leaflet before use. 
Pred uporabo preberite navodilo za uporabo, kjer boste našli opozorila za kirurga.
In common with other inhalational anaesthetics, the minimum alveolar concentration (MAC) of sevoflurane is reduced by the concurrent administration of benzodiazepines and opioids. 
Tako kot pri drugih inhalacijskih anestetikih sočasna uporaba benzodiazepinov in opioidov zmanjša minimalno alveolarno koncentracijo (MAC) sevoflurana.
The possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs and cats cannot be ruled out. 
Ni mogoče izključiti možnosti, da bi sevofluran pri dovzetnih psih in mačkah sprožil epizode maligne hipertermije.
In order to minimise exposure to sevoflurane vapour, the following recommendations are made: 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Da bi kar najbolj zmanjšali izpostavitev hlapom sevoflurana, priporočamo naslednje:
In cats, transient increases in AST and ALT may occur with sevoflurane, however, hepatic enzymes tend to remain within the normal range. 
Pri mačkah se lahko pri sevofluranu pojavi prehodno zvišanje aspartatne aminotransferaze (AST), alaninske aminotransferaze (ALT), medtem, ko jetrni encimi ostanejo v normalnem območju
Long duration, low-flow sevoflurane anaesthesia should be avoided due to the risks of Compound A accumulation. 
Zaradi nevarnosti kopičenja spojine A se je treba dolgotrajni nizkopretočni sevofluranski anesteziji izogibati.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Carton box 
PODATKI NA STIČNI OZ. PRIMARNI OVOJNINI Nalepka za steklenice
Neuromuscular blocking agents have been used in cats anaesthetised with sevoflurane without any unexpected effects 
Neuromuskularni blokatorji so bili uporabljeni pri mačkah,
benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations. 
Anestezijske sheme, ki vključujejo premedikacijo z opioidi, alfa-2-agonisti, benzodiazepini ali fenotiazini, dopuščajo uporabo nižjih vzdrževalnih koncentracij sevoflurana.
IRELAND 
IRSKA.
Teл: +353 91 841788 
IE - Ireland Teл: +353 91 841788
This means that there is more evidence to come about the vaccine, which the company is required to provide. 
To pomeni, da se pričakujejo dodatni dokazi o cepivu, ki jih mora zagotoviti podjetje.
Further information on Ervebo can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Ervebo. 
Dodatne informacije o zdravilu Ervebo so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Ervebo.
What measures are being taken to ensure the safe and effective use of Ervebo? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ervebo?
Ervebo can only be obtained with a prescription and should be used in accordance with official recommendations. 
Zdravilo Ervebo se izdaja le na recept in ga je treba uporabljati v skladu z uradnimi priporočili.
The European Medicines Agency therefore decided that Ervebo's benefits are greater than its risks and that it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Ervebo večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
People received a single dose of Ervebo either immediately or after 21 days. 
Osebe so prejele enkratni odmerek zdravila Ervebo takoj ali po 21 dneh.
Since Ervebo has been given conditional authorisation, the company that markets Ervebo will provide additional details on certain aspects of the production process. 
Ker je zdravilo Ervebo dobilo pogojno dovoljenje, bo podjetje, ki ga trži, zagotovilo dodatne podrobnosti o nekaterih vidikih proizvodnega procesa.
Ervebo is given by a trained healthcare worker. 
Zdravilo Ervebo daje usposobljen zdravstveni delavec.
As for all medicines, data on the use of Ervebo are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Ervebo stalno spremljajo.
The most common side effects with Ervebo (which may affect more than 1 in 10 people) are pain, swelling and redness at the injection site, headache, fever, muscle pain, tiredness and joint pain. 
Najpogostejši neželeni učinki zdravila Ervebo (ki se lahko pojavijo pri več kot 1 od 10 oseb) so bolečina, oteklina in pordelost na mestu injiciranja, glavobol, zvišana telesna temperatura, bolečine v mišicah, utrujenost in bolečine v sklepih.
Amongst the 2,108 people who received immediate vaccination, none had Ebola virus disease between 10 days and 31 days after vaccination; amongst those whose vaccination was delayed (1429 people), 10 developed the disease within 31 days after vaccination. 
Pri 2 108 osebah, ki so bile cepljene takoj, se v 10 do 31 dneh po cepljenju bolezen ebola ni pojavila; pri tistih, ki so bile cepljene pozneje (1 429 oseb), pa se je bolezen v 31 dneh po cepljenju razvila pri 10 osebah.
Other information about Ervebo 
Druge informacije o zdravilu Ervebo
What are the risks associated with Ervebo? 
Kakšna tveganja so povezana z zdravilom Ervebo?
The vesicular stomatitis virus itself has little or no effect on humans. 
Virus vezikularnega stomatitisa ne vpliva ali le malo vpliva na ljudi.
The effectiveness of the vaccine to protect against confirmed Ebola virus disease was measured by comparing the number of cases occurring 10 to 31 days after vaccination in the group of people vaccinated immediately, versus the number of cases in the group of people who were vaccinated later. 
Učinkovitost cepiva pri zaščiti pred potrjeno boleznijo ebola je bila izmerjena na podlagi primerjave števila primerov pojava bolezni v 10 do 31 dneh po cepljenju v skupini oseb, ki so bili cepljene takoj, in števila primerov bolezni v skupini oseb, ki so bile cepljene pozneje.
Ervebo must not be used in people who are hypersensitive (allergic) to rice or to any ingredients of the vaccines. 
Zdravilo Ervebo se ne sme uporabljati pri osebah, ki so preobčutljive (alergične) na riž ali katero koli drugo sestavino cepiva.
Why is Ervebo authorised in the EU? 
Zakaj je bilo zdravilo Ervebo odobreno v EU?
What benefits of Ervebo have been shown in studies? 
Kakšne koristi zdravila Ervebo so se pokazale v študijah?
An overview of Ervebo and why it is authorised in the EU 
Pregled zdravila Ervebo in zakaj je odobreno v EU
Ervebo has been given ‘conditional authorisation'. 
Zdravilo Ervebo je pridobilo „pogojno dovoljenje za promet“.
The vaccine only contains one protein from Zaire Ebola virus and cannot cause the disease. 
Cepivo vsebuje samo eno beljakovino iz virusa Ebola Zaire in ne more povzročiti bolezni.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ervebo have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Ervebo upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Ervebo is effective in protecting adults from Ebola virus disease; however, the duration of this protection is currently unknown. 
Zdravilo Ervebo je učinkovito pri zaščiti odraslih pred boleznijo ebola, vendar trajanje te zaščite trenutno ni znano.
What is Ervebo and what is it used for? 
Kaj je zdravilo Ervebo in za kaj se uporablja?
Side effects with Ervebo were similar to those of most vaccines; they were mild to moderate in intensity and generally lasted less than a week. 
Neželeni učinki zdravila Ervebo so podobni kot pri večini cepiv; so blagi do zmerno intenzivni in običajno trajajo manj kot teden dni.
For more information about using Ervebo, see the package leaflet or contact your doctor or pharmacist. 
Dodatne informacije o uporabi zdravila Ervebo si oglejte v navodilu za uporabo ali pa se posvetujte z zdravnikom ali farmacevtom.
In general, these reactions occur within 7 days after vaccination, were mild to moderate in intensity and resolved in less than a week. 
Običajno se te reakcije pojavijo v 7 dneh po cepljenju, so blage in izzvenijo v manj kot tednu dni.
It is given as a single 1 ml injection into the muscle around the shoulder (the deltoid) or a muscle of the thigh. 
Cepivo se injicira v enkratnem 1-mililitrskem odmerku v ramensko (deltoidno) ali stegensko mišico.
When a person receives the vaccine, it triggers an immune response against the virus protein. 
Ko oseba prejme cepivo, to povzroči imunski odziv na beljakovino virusa.
Later, when the person comes into contact with the actual virus, the immune system recognises the virus protein and is already prepared to attack the virus and so protects the person from Ebola virus disease. 
Ko oseba pozneje pride v stik z dejanskim virusom, imunski sistem prepozna beljakovino virusa in je že pripravljen za napad na virus, tako da zaščiti osebo pred ebolo.
What information is still awaited for Ervebo? 
Katere informacije o zdravilu Ervebo še pričakujemo?
Side effects reported with Ervebo are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Ervebo, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
A main study showed that Ervebo was effective in preventing Ebola virus disease in adults at risk of infection during an outbreak. 
Glavna študija je pokazala, da je zdravilo Ervebo učinkovito preprečevalo ebolo pri odraslih, pri katerih obstaja tveganje okužbe med izbruhom bolezni.
The study was conducted in Guinea during an Ebola outbreak and involved people who were either direct contacts or contacts of contacts of someone who had Ebola virus disease. 
Študija je bila izvedena v Gvineji med izbruhom ebole in je zajela osebe, ki so bile bodisi v neposrednem stiku z obolelim za ebolo bodisi v stiku z osebami, ki so bile v stiku z obolelimi.
Healthcare workers and other carers who have been vaccinated with Ervebo should also continue to apply standard precautions for safe injection and hygiene and wear personal protective equipment when caring for patients with known or suspected Ebola virus disease. 
Zdravstveni delavci in drugo negovalno osebje, ki so bili cepljeni s cepivom Ervebo, bi morali pri oskrbi bolnikov, za katere je znano, da imajo ebolo, ali pri katerih obstaja sum nanjo, še naprej uporabljati običajne previdnostne ukrepe za varno injiciranje in higieno ter opremo za osebno zaščito.
Ervebo is a vaccine to protect adults aged 18 years and older against Ebola virus disease caused by the Zaire Ebola virus. 
Zdravilo Ervebo je cepivo za zaščito odraslih, starih 18 let in več, pred ebolo, ki jo povzroča virus Ebola Zaire.